Cediranib (AZD2171): Phase II Study in Patients With Alveolar Soft Part Sarcoma
Cediranib (Recentin, AZD2171) is an inhibitor of VEGF (Vascular Endothelial Growth Factor) receptors. Therefore, the drug inhibits angiogenesis: the formation of new blood vessels. Angiogenesis, in the context of cancer, enables blood supply to tumors, resulting in tumor growth and spread. Cediranib is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral […]